Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) holds the promise of developing an all-oral HCV regimen that can be competitive in the evolving HCV treatment landscape. It is the only small-cap biotech company with HCV drug candidates in three key classes – NS5A, nucleotide NS5B polymerase and protease inhibitors. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) shares after opening at $2.70 moved to $2.87 on last trade day and at the end of the day closed at $2.85. Company price to cash ratio as 2.26. Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) showed a negative weekly performance of 7.47%.
On april 29, 2014, Amicus Therapeutics, Inc. (NASDAQ:FOLD), announced that the late stage trail of its fat storage disorder treating drug showed effective results. Amicus Therapeutics, Inc. (NASDAQ:FOLD), shares ended the day on $2.22. Amicus Therapeutics, Inc. (NASDAQ:FOLD), return on equity ratio is recorded as -144.30% and its return on assets is -64.10%. . Amicus Therapeutics, Inc. (NASDAQ:FOLD), yearly performance is -31.69%.
Many investors appear to be quite bearish on ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), especially if you look at the percentage of the float that is sold short for this stock. Currently, 21.7% of the float is sold short, suggesting an extreme level of bearishness for ZIOP . ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), shares moved up 5.26% in last trading session and was closed at $3.60, while trading in range of $ 3.25 – 3.62. ZIOPHARM Oncology Inc. (NASDAQ:ZIOP), year to date (YTD) performance is -17.05%.
On April 30, 2014, Genetic Technologies Limited (ADR) (NASDAQ:GENE), announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Genetic Technologies Limited (ADR) (NASDAQ:GENE), weekly performance is -4.23%. On last trading day company shares ended up $1.36. Genetic Technologies Limited (ADR) (NASDAQ:GENE), distance from 50-day simple moving average (SMA50) is -11.15%. Analysts mean target Price for the company is $2.50.
Leave a Reply